Locations:
Search
Bispecific antibody bridging therapy deepens durability of BCMA CAR T-cell therapy without overlapping toxicities in patients with relapsed/refractory multiple myeloma
Phase 2 study brings pivotal advances in treatment efficacy and safety for the most challenging-to-treat population
Advances in genomics, spinal fluid analysis, wearable-based patient monitoring and more
Patient with quadruple refractory multiple myeloma achieves complete response with cell therapy
Advertisement
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy
Distinct baseline immune profiles can predict response and resistance to different types of CAR-T cells.
Integrated care model reduces length of stay, improves outpatient pain management
Case study of radial-to-axillary nerve transfer for tumor-related deltoid nerve injury
National Blood Clot Alliance collaborates with faith-based organizations on first-of-its-kind church bus tour
AI-driven tools can streamline enrollment and improve efficiency across clinical trials.
Patient achieves complete remission from aggressive marginal zone lymphoma with liso-cel
Advertisement
Advertisement